Why sophisticated investors are hard to convince.
Sophisticated investors have seen too many clean stories. They trust complexity presented honestly more than simplicity presented smoothly.
The job is not to make your science look simple. It is to make it legible, credible, and impossible to poke a hole in. That has to hold in the room where the decision gets made.
Doing that well is a discipline of its own, one we call investor science communication.
What we build for the room where capital moves.
Investor deck visual architecture
The structural backbone of the raise: a deck where the scientific argument is legible, defensible, and impossible to poke a hole in.
Case note: Cidara CD388 →MoA & data visualization for investors
Mechanism and data made legible to the holder, without diluting the science.
Case note: Kartos Navtemadlin →Roadshow & milestone communication
Communication paced to the calendar and consistent from first meeting to close, the through-line that holds across every milestone.
Clinical readout communication
The readout framed honestly: what it shows, what it doesn't, and why it matters.
Case note: aTyr Efzofitimod →
A proven adjuvant, CpG 1018, carried from a marketed hepatitis B vaccine into a shingles candidate and beyond. One platform, a whole pipeline.
A company the market read as one product. The platform beneath it was the story that wasn't landing.
One platform story, told straight. The pipeline's value made legible to the market. Dynavax was acquired by Sanofi in 2026 for $2.2 billion.
Questions about investor science communication.
How do biotech companies present clinical data to investors?
By translating mechanism, data, and pipeline into a narrative the investment audience can evaluate — presenting complexity honestly rather than smoothing it away.
What makes a strong biotech investor deck?
Visual architecture built for the room: a defensible scientific argument, legible data, and a mechanism a sophisticated holder can follow and trust.
How do you explain a mechanism in an IR presentation?
With accurate MoA and data visualization built from the argument backward, so the science is legible and credible to a skeptical investor.
What is Reg FD and why does it matter for IR materials?
Regulation Fair Disclosure governs how public companies share material information. IR materials must be Reg FD-aware so communication stays consistent, fair, and built to survive scrutiny.